Cagrilintide (10 mg Vial) Dosage Protocol

Quickstart Highlights

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration^[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake^[2]^[3]. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile^[4]^[5].

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.

Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).

Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 0.0333 mg (33.3 mcg) on a U‑100 insulin syringe.

Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.

Week/Phase	Weekly Dose (mg)	Units (per injection)	Volume (mL)
Weeks 1–2	0.6 mg	18 units	0.18 mL
Weeks 3–4	1.2 mg	36 units	0.36 mL
Weeks 5–6	2.4 mg	72 units	0.72 mL
Weeks 7–16 (Maintenance)	4.5 mg	135 units	1.35 mL

Note: The maintenance dose of 4.5 mg requires 135 units (1.35 mL), which exceeds a standard U‑100 insulin syringe capacity. Use a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) for doses above 1.0 mL. For titration doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming or vigorous agitation.

Gently swirl or roll until fully dissolved (do not shake).

Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.

Important: This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies Needed

Plan based on an 8–16 week weekly protocol with gradual titration.

Peptide Vials (Cagrilintide, 10 mg each):

8 weeks ≈ 2 vials (17.4 mg total needed)
12 weeks ≈ 4 vials (35.4 mg total needed)
16 weeks ≈ 6 vials (53.4 mg total needed)

Syringes:

Weeks 1–6 (doses ≤72 units): U‑100 insulin syringes work well
Weeks 7+ (doses >100 units): 3 mL syringes with 25–27G subcutaneous needles
Per week: 1 syringe
8 weeks: 8 syringes
12 weeks: 12 syringes
16 weeks: 16 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
16 weeks (6 vials): 18 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each week.

Per week: 2 swabs
8 weeks: 16 swabs
12 weeks: 24 swabs
16 weeks: 32 swabs → recommend 1 × 100‑count box

View Supplier

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support satiety, reduce food intake, and promote weight management over time^[2]^[4].

Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate).

Dose Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.

Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for practical volume measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.

Research Disclaimer